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Maternal serum alpha-fetoprotein (MSAFP) and human 
chorionic gonadotrophin (MShCG) concentrations were well known 
to be associated with adverse outcomes and complications in 
singleton pregnancy. In twin pregnancy, there is limited 
information concerning these associations, especially among 
ethnic Chinese women. 
The aim of the study is to establish a normogram of MSAFP 
and MShCG concentration for twin pregnancies in Chinese and to 
assess the predictiveness of these hormones for adverse pregnancy 
outcomes and complications. 
Maternal sera of twin pregnancies were obtained at 2-weekly 
intervals from 14-24 weeks and tested for alpha-fetoprotein (A FP) 
and human chorionic gonadotrophin (hCG) with microparticle 
enzyme immunoassay (MEIA). Median values of both hormones for 
each gestation week were calculated. The association between both 
hormones and adverse outcomes or complications was analyzed by 
receiver operating characteristic (ROC) curves. 
i 
The median values of MSAFP and MShCG in twin pregnancy 
among Chinese were approximately double those of singleton 
pregnancy in Chinese and are obviously higher than those of 
Caucasian. By receiver operating characteristic curve analysis, 
MSAFP taken at 22-23 week appears to be most predictive of most 
adverse outcomes (preterm delivery, pregnancy induced 
hypertension and growth discordant). Even so, the best curve has 
an area under curve of only 0.713. Maternal weight adjustment 
did not improve the performance of the tests in predicting the 
adverse outcomes. 
In conclusion, Chinese should have their own data base of 
MSAFP and MShCG concentrations in twin pregnancies. Though 
elevated maternal serum alpha-fetoprotein and human chorionic 
gonadotrophin concentration were significantly associated with 
adverse outcomes, their clinical use as a screening test is limited 
because of poor sensitivity and specificity. On the other hand, if 
MSAFP is measured for other indications and is found to be 
elevated (>2 multiples of the median), these twin pregnancies 
should have extra antenatal surveillance because of their high risk 
of adverse outcomes and complications. 
ii 
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CHAPTER I 
INTRODUCTION AND OBJECTIVES 
The association between raised matemal and amniotic fluid 
alpha-fetoprotein (AFP) and open neural tube defect (ONTD), which 
is a major congenital malformation with an incidence of about 6-8 
per thousand deliveries in the United Kingdom, was first reported 
in early 1970s (Brock and Sutcliffe, 1972; Brock et al, 1973). 
Subsequent researches showed that second trimester matemal 
serum alpha-fetoprotein (MSAFP) is an effective test to screen for 
open neural tube defect (Report ofU.K. Collaborative study, 1977). 
Common causes of false positive screening result, i.e. elevated 
MSAFP concentration without ONTD, include underestimation of 
gestational age, multiple pregnancy, fetal death, and other fetal 
abnormalities such as gastroschisis. Audits of such screening 
programs found that those pregnancies with elevated MSAFP 
concentration in mid-trimester of unidentifiable cause were at 
higher risk of pregnancy complications and adverse perinatal 
outcomes, including pre-eclampsia, premature delivety, low birth 
weight (LBW) infants, intrauterine growth retardation (IUGR), and 
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placental abruption. (Wald et al., 1977; Smith, 1980; Evans and 
Stokes, 1984; Burton and Dillard, 1986). 
The association between low MSAFP concentration and fetal 
chromosomal abnormalities was first reported in 1984 (Merkatz et 
aL). Others demonstrated that fetal chromosomal abnormalities 
are also associated with elevated matemal serum chorionic 
gonadotrophin (hCG) and low oestriol (E3) concentrations (Bogart 
et al, 1987, Canick et al, 1988). This formed the basis of second 
trimester biochemical screening for Down's syndrome. Once again, 
it was later reported that elevated mid-trimester maternal serum 
human chorionic gonadotrophin (MShCG) concentration in 
chromosomally normal singleton pregnancies was also associated 
with adverse pregnancy complications and outcomes, such as pre-
eclampsia, small for gestational age (SGA) infants fWenstrom et al, 
1994; Tanaka, etal, 1993). 
In twin pregnancies, there is limited information concerning 
the association between MSAFP or MShCG concentration and 
adverse pregnancy complications. Theoretically, MSAFP and 
MShCG concentrations in twin pregnancies should at least double 
those in singleton pregnancies. This has been supported by several 
studies performed in Caucasian countries (Wald et al, 1991; 
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Canick et al.， 1990). However, there is no corresponding 
information for Chinese. Several reports had suggested that Asian 
has a higher MSAFP and MShCG concentrations (OBrien et al.， 
1993; Muller et al, 1994). 
The objective of this thesis were to establish a reference 
range for MSAFP and MShCG concentrations for twin pregnancies 
in Chinese women; and to investigate the effectiveness of using 





II.A. Matemal Serum Alpha-fetoprotein Screening in 
Singleton Pregnancies 
n.A. 1. Physiology of Alpha-fetoprotein 
Alpha-fetoprotein (AFP) was first discovered in fetal serum in 
1956 (Bergstrand and Czar). It is a glycoprotein of molecular 
weight of 68,000 daltons. It is produced initially in the fetal yolk 
sac and subsequently in the fetal liver (Gitlin, 1975). The 
physiological function of AFP is yet unclear, but AFP has been 
considered to be the main fetal plasma protein during early 
pregnancy. Fetal concentration rises rapidly to a peak level of 
approximately 30 g/1 at 12 to 13 weeks of gestation (Gitlin and 
Boseman, 1966) and gradually declines towards term to a 
concentration of approximately 50 mg/1 in cord blood. The AFP 
concentration continues to fall throughout the first year of life but 
do not reach zero. 
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AFP escapes into the amniotic fluid via fetal urine and also 
through any surface defect of the fetus. It is transported to 
matemal serum either by transplacental transfer, or by diffusion 
across fetal membranes. There is a concentration gradient between 
fetal serum, amniotic fluid and matemal serum. By 13 weeks of 
gestation, amniotic fluid AFP reaches its peak concentration of 
around 20 mg/l, which is approximately 150 to 200 times less 
than that of fetal serum concentration (Crandall et al, 1987; 
Drugan et aL，1988; Elejalde et al, 1990; Palomaki et al, 1993). 
Thereafter, amniotic fluid AFP declines steadily while MSAFP 
concentration continues to increase until 28-32 weeks of 
gestation. The exact mechanism of this change in gradient has not 
been fully understood, but one possible explanation might be the 
fact that the surface area for both transplacental and 
transamniotic diffusion increases rapidly during this period. 
II.A.2. Historical Background of Screening by Alpha-
fetoprotein 
Brock and colleagues reported in 1973 that maternal serum 
alpha-fetoprotein (MSAFP) concentrations was elevated in patients 
canying a fetus with anencephaly. Based on data collected from 
18847 pregnancies without fetal open neural tube defect (ONTD) 
12 
and 301 pregnancies with ONTD, the U.K. Collaborative Study 
(1977) reported a sensitivity of over 80% at a false positive rate of 
3% by using MSAFP as a screening test for ONTDs, if abnormal 
test was defined as one in which AFP was above 2.5 times of the 
normal median. MSAFP concentration was expressed as multiples 
of the median (MoM), so as to correct for the gestation-dependency 
of AFP. Because of these encouraging results, MSAFP has become 
a common prenatal screening test for congenital anomalies among 
the Caucasians. 
II.A.3. Factors that Influence Matemal Serum Alpha-
fetoprotein Concentration 
Several factors are known to affect MSAFP concentration. 
The most important one is gestational age. The hormonal level 
increases as gestational age advances (U.K. Collaborative Study, 
1977). To correct for gestational dependency, individual test 
results were expressed as multiples of the median (MoM) of the 
same gestational age, although alternatively the same objective 
may be achieved by using multiple regression. It follows naturally 
that inaccurate gestational estimation will have substantial effect 
on the subsequent interpretation of AFP test results. 
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Matemal weight has been found to be negatively associated 
with MSAFP. Large women tends to have lower serum AFP, 
probably because of dilutional effect by larger maternal blood 
volume {Wsld et al, 1981). MSAFP is also ethnic dependent. A 
higher MSAFP profile among Asians has been reported (OBrien et 
aZ.，1993 and 1997). Mothers with insulin dependent diabetes also 
tend to have lower MSAFP concentration (Wald et al” 1979). It is 
not surprising that MSAFP is higher in multiple pregnancies (Table 
II.A). 
II.A.4. Elevated Matemal Serum Alpha-fetoprotein 
Concentration and Adverse Pregnancy Outcomes and 
Complications 
Follow-up studies of pregnancies with elevated MSAFP at 
second trimester without identifiable causes showed that these 
pregnancies are at higher risk of adverse outcomes or 
complications. 
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Table H.A: Median of maternal serum aIpha-fetoprotein concentrations in 
twin pregnancies in the mid-trimester compared with singleton 
Reference Number of Twin Ratio of Median^ 
Pregnancies 
Thom et al (1984) 100 1 90 
Qhoshetal (1982) 219 2.52 
Johnson et al (1990) 13 8 2 5 
CanickeZa/.(1990) 35 2.32 
Alpert^/a/. (1990) 51 1.58 
Cuckle et al (1990) 169 1 90 
Wald etal (1991) 200 2.13 
Spencer et al (1994) 420 2.28 
Bamabei^ /a/. (1995) 225 1 91 
Total 1557 2.17* 
* Weighted geometric mean MoM 
a denotes the median of multiple pregnancy to singleton pregnancy ratio 
Source: Modified from Aitken, 1995. 
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II.A.4.a. Low Birth Weight 
Brock and associates (1977) first reported the association 
between low birthweight (< 2500 g) and raised matemal serum 
alpha-fetoprotein concentration. They found that 10.7 per cent of 
women who gave birth to a low birthweight baby had a MSAFP 
concentration greater than 2.3 MoM，compared to the background 
incidence of 4.2 per cent. Wald and colleagues (1977) 
demonstrated that the incidence of low birth weight premature 
babies and perinatal loss was increased in women with MSAFP 
greater than 3 MoM. However, they had included cases underwent 
amniocentesis which has been shown to be associated with 
adverse pregnancy outcome and therefore may be a confounding 
factor. Burton (1988) noted an incidence of 15 per cent oflow birth 
weight infants among women with MSAFP concentrations greater 
than 2.5 MoM, compared to an incidence of only 7.2 per cent 
among those with normal serum alpha-fetoprotein concentrations. 
Similarly, it has been reported that raised MSAFP 
concentration was associated with preterm delivety (Davis et al, 
1992; Waller etal, 1996; Smith, 1980). 
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Brock and co-workers (1982) assessed serum alpha-
fetoprotein concentrations in 382 women throughout pregnancy 
and found that raised maternal serum alpha-fetoprotein 
concentration was associated with low birthweight (<2500 g) only 
when samples were taken before 20 weeks. 
II.A.4.b. Fetal Loss 
Elevated MSAFP concentration has been shown to be 
associated with fetal loss. Nelson and associates (1987) found that 
20 per cent of the patients with MSAFP concentration greater than 
5 MoM had fetal loss. This finding suggested that even patients 
had a viable fetus at the time of investigation would have 
increased risk for fetal loss subsequently. Burton (1988) reported a 
fetal loss rate of 4 per cent after 20 weeks of gestation in women 
who have an elevated MSAFP concentration and a viable fetus at 
the time of ultrasound examination. Schnittger and Kjessler (1984) 
reported that MSAFP screening could predict 30 per cent of 
perinatal loss with a cutoff at 1.8 MoM. 
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II.A.4.c. Pregnancy Induced Hypertension 
Walter and colleagues (1985) reported that 13 per cent of 
patients with raised MSAFP concentration developed pre-
eclampsia as compared with 1 per cent in controls. Moore and 
Redman (1983) reported a significantly higher incidence of pre-
eclampsia if MSAFP concentration was elevated (3 of 24 patients) 
when compared with controls (0 in 48) {p<0.05). Hamilton and co-
workers (1985) found that the incidence of pregnancy induced 
hypertension (PIH) was significantly increased in patients with 
MSAFP concentration greater than 2 MoMs. Milunsky and 
colleagues (1989) found an increased risk of 2.3-fold for toxaemia 
in patients with raised MSAFP. 
II.B. Matemal Serum Human Chorionic Gonadotrophin 
Screening in Singleton Pregnancies 
II.B. 1. Physiology of human chorionic gonadotrophin 
Human chorionic gonadotropin (hCG) is a glycoprotein of 
molecular weight of approximately 35,000 daltons comprised of 
two unidentical subunits designated as alpha and beta. The alpha 
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subunit is essentially analogous to the alpha subunit of other 
pituitaty peptide hormones, specific biological activity is 
contributed by the beta subunit. Assays specific for hCG are 
designed to detect the beta subunit, even if the assay is specific for 
total hCG. Therefore many assays for total hCG are referred to as 
total beta-hCG assays. These assays should not be confused with 
free-beta-hCG assays designed to detect free beta subunit only. In 
spite of the biological specificity of the beta-hCG subunit, there is 
considerable homology with the beta subunit of luteinizing 
hormone (LH). Therefore, it is important to select an assay capable 
of detecting hCG without significant interference from luteinizing 
hormone. 
Human chorionic gonadotropin is first produced by the 
trophoblast of the blastocyst and later in pregnancy by the chorion 
and placenta. It prevents the regression of the corpus luteum after 
fertilization, enabling the corpus luteum to secrete progesterone 
and oestrogen, which are essential to maintain an early 
pregnancy. Matemal serum hCG concentrations increase 
exponentially between 3 and 10 weeks of gestation. 
Concentrations reach a peak during the first trimester (about 
100,000 mIU / ml) and then decline during the second and third 
trimester. 
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Human chorionic gonadotropin is excreted directly into the 
maternal circulation by the placenta through villous interface. It 
accumulates in amniotic fluid by two routes: via fetal micturition 
and diffusion directly from the placenta (Cuckle et al, 1991). Any 
leakage or defect of the feto-maternal barrier or an increase in the 
placental villous surface area may lead to elevation of MShCG 
concentration. 
II.B.2.Historical Background of Screening by human Chorionic 
Gonadotrophin 
The finding that MSAFP is associated with fetal 
chromosomal abnormalities has lead to the speculation of similar 
association with other feto-placental products (Chard et al, 1984). 
Bogart and co-workers (1987) demonstrated that elevated 
maternal serum human chorionic gonadotrophin concentration is 
associated with fetal Down's syndrome. This was confirmed by 
others authors (Wald et al, 1988; White et al，1989; Heyl et al, 
1990). Review of data collected through Down's syndrome 
screening programme suggested that elevated matemal serum 
hCG is associated with subsequent pregnancy complications. 
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ILB.3. Factors that Influence Maternal Serum Human 
Chorionic Gonadotrophin 
Matemal serum human chorionic gonadotrophin 
concentration is influenced by several factors. Firstly, it varies 
considerably with gestation age. Secondly, matemal weight exerts 
similar effect on maternal serum hCG concentration as on AFP 
concentration. Ethnicity is also an important factor. It has been 
reported that Asian has a higher maternal serum hCG 
concentration than Caucasian (Muller et al, 1994; OBrien et al” 
1997). Patients with multiple pregnancies have larger placental 
size and more human chorionic gonadotrophin production and 
therefore have higher serum concentration of hCG (Canick et al, 
1990; Nebiolo etal, 1991). 
II.B.4. Elevated Matemal Serum Human Chorionic 
Gonadotrophin Concentration and Pregnancy 
Complications 
Gravett and colleagues (1992) reported that matemal serum 
hCG concentration greater than 5 MoM was associated with higher 
pregnancy complications. In their study, 7 of 3000 pregnancies 
had serum hCG concentration greater than 5 MoM, ofwhich 5 had 
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premature deliveries, two had pre-eclampsia and HELLP 
syndrome, and one had abruptio placentae. 
Among 6011 pregnancies, Gonen and associates (1992) 
found that 284 had an unexplained elevated hCG concentration 
above 2.5 MoM. There was an increased risk for hypertensive 
disorders (odds ratio = 4.4, p<0.001) among this subgroup of 
patients. 
Wenstrom and co-workers (1994) found that matemal 
serum hCG concentration was significantly related to preterm 
delivety (p=0.04) and pre-eclampsia (p=0.02). 
Ashour and associates (1997) reported that maternal serum 
hCG concentration greater than 2 MoM was associated with pre-
eclampsia. Muller and colleagues (1996) found that elevated 
human hCG was significantly related to pre-eclampsia but not 
pregnancy-induced hypertension. 
Conversely, Santolaya and colleagues (1992) did not find 
any association between elevated hCG concentration (>2.5 MoM) 
and adverse pregnancy outcome. 
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The overall evidence suggests that elevated maternal serum 
hCG is associated with adverse pregnancy outcomes or 
complications. 
II.B.5. Maternal Serum AFP and hCG Concentrations and 
Adverse Outcomes or Complications in Twin 
Pregnancies 
In 1978, Wald and associates showed that maternal serum 
aIpha-fetoprotein (MSAFP) concentration was approximately twice 
that of for singleton pregnancies among Caucasian not 
complicated by fetal open neural tube defect (ONTD). The same 
authors also detected a negative association between alpha-
fetoprotein (AFP) concentration and birth weight. In 1982, Ghosh 
and co-workers demonstrated that the median alpha fetoprotein 
concentration in twin pregnancies was about 2.5 times of the 
median of singleton pregnancies. The outcome in twin pregnancies 
with matemal serum alpha-fetoprotein concentrations greater 
than 5 MoM was significantly worse than those pregnancies with 
concentrations less than 5 MoM. In addition, there was a 
significant negative correlation between MSAFP concentrations 
and combined birthweight of both twins. 
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In 1990, Johnson and colleagues stated that increasing 
matemal serum alpha-fetoprotein concentrations correlated 
significantly with increasing incidence of congenital anomalies, 
fetal and neonatal deaths, twin-to-twin discordance and 
premature delivety which was defined as delivety before 34 weeks 
of gestation, beginning at a maternal serum alpha-fetoprotein 
concentration of 4.0 MoM for singleton pregnancy. In addition, 
there was a highly significant negative correlation between MSAFP 
and birth weight. Furthermore, an inverse relationship between 
matemal serum alpha-fetoprotein concentration and normal 
outcome, defined as live bom twins delivered at greater than 34 
weeks of gestation and both surviving, was observed. Because the 
incidence of all measures of adverse outcome in this in this study 
was shown to be significantly increased if MSAFP concentration 
was 4.0 MoM (of singleton) or above, 4.0 MoM may be the upper 
limit of normal for twins. 
However, Walker and Patel (1986) could not demonstrate 
any statistical significant difference in AFP level between small-for-
date and appropriate-for date infants. In this study, gestational 
age was confirmed by ultrasound scan in all cases, whilst in the 
previous study, gestational ages were estimated by menstrual 
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histOty only in the majority of cases, which might have lead to 
inaccurate estimation of MoM due to inaccurate dating. 
To my knowledge, there is no publication concerning the 
association of matemal serum human chorionic gonadotrophin 
concentration and adverse pregnancy outcomes or complications 
in twin pregnancies. 
II.C. Mechanism for the Association between Adverse 
Outcomes and Elevated Matemal Serum AIpha-
fetoprotein and Human Chorionic Gonadotrophin 
The mechanism for the association between adverse 
pregnancy outcome and matemal serum alpha-fetoprotein and 
human chorionic gonadotropin is unknown, although most 
researchers consider that the primary abnormality is in the 
placenta. 
It has been suggested that intra-uterine growth retardation 
(IUGR) might be caused by chronic fetomaternal haemorrhage 
(Salafia, et al.，1988) which will lead to leakage of AFP into 
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maternal circulation. If this hypothesis is correct, the association 
between elevated MSAFP and low birth weight can be explained. 
Perkes and co-workers (1982) detected a significant increase 
in the incidence of cystic spaces in second trimester placenta 
among those pregnancies with raised MSAFP. Through these cystic 
spaces，fetal blood may escape into maternal circulation without 
entering the amniotic fluid. However, Perkes and co-workers 
(1982) failed to prove that these lesions are an early sign of 
placental insufficiency. Alternatively, Salafia and associates (1988) 
suggested that chronic villitis may be a cause. They found 
placental vascular lesions at term suggesting uterine vascular 
disease. 
On the other hand, placental insufficiency leads to reduced 
oxygen supply, which results in intra-uterine growth retardation 
(IUGR) in the fetus and cytotrophoblastic hyperplasia, causing an 
increase in MShCG (Rushton, 1991). 
Heinonen and colleagues (1996) suggested that velamentous 
umbilical cord insertion (VCI) is a cause for the elevation of hCG, 
They found that velamentous umbilical cord insertion is 
significantly related to adverse pregnancy outcome and patients 
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with velamentous umbilical cord insertion had significantly higher 




III.A. Study Population 
Pregnant mothers who booked for confinement in the Prince 
ofWales Hospital were invited into the study from September 1994 
to September 1996. Ethical permission had been obtained from 
the local committee of the Chinese University of Hong Kong. 
Inclusion criteria are as follows: 
1. twin pregnancy 
2. Ethnic Chinese 
3. 14-24 weeks of gestation 
4. no histoty or clinical evidence of liver disease at time 
of investigation (Adinolfi et al.，1975; Urabach et al, 
1987; Yachnin et al.，1978) 
5. no gestational trophoblastic disease 
6. consented for participation into the study 
Gestational ages were calculated from the last menstrual 
period (LMP). If this was not known or the ultrasound scanning at 
booking demonstrated a discrepancy of more than 10 days in first 
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trimester or 2 weeks in second trimester, the gestational age was 
calculated according to the ultrasound scan measurement. 
Obstetric management was independent of the results of the 
study. 
III.B. Sample Collection and Analysis 
Ten milliliters of maternal venous blood was taken at 2-
weekly intervals. The samples were centrifuged at 4000 rpm within 
2 hours of collection. The separated serum were stored in aliquots 
at -80 °C pending analysis. At completion of 24 weeks ofgestation, 
the serum samples were tested for alpha-fetoprotein (AFP) and 
total beta-human chorionic gonadotropin (p-hCG) with automated 
Microparticle Enzyme Immunoassay (MEIA) (IMx, Abbot, USA) 
(Flore et al, 1988; Keller et al, 1991). All samples from each 
woman were tested within the same assay to avoid inter-assay 
variation. 
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III.C. CKnical Information 
Demographic data of the pregnant mothers, pregnancy 
outcomes and information on deliveries were obtained. Antenatal 
complications if any were also recorded (Appendix 1). 
Fetal death was defined as death before expulsion of the 
infant (Maher et al, 1994). Preterm delivety was defined as 
delivety less than 37 completed weeks (Pergament et al.，1995). 
Premature delivety was defined as birth before 34 completed 
weeks. Birth weight of less than 2.5 kg was defined as low birth 
weight {Lieppman et aL, 1993). Growth discordant was defined as 
inter-twin birth rate difference of greater than 20 per cent 
(Johnson et al, 1990). The severity and classification of pregnancy 
induced hypertension was listed in Appendix 2 (Davey, 1995). 
III.D. Microparticle Enzyme Immunoassay 
III.D.1. Principles 
Submicron microparticles (0.47 i^m in diameter) are coated 
with a capture molecule specific for the analyte being measured. A 
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suspension of microparticles provides greater effective surface area 
than polystyrene bead or coated-tube solid phase used 
conventionally. The increase in surface and shortening of the 
diffusion distance between analyte and capture molecules on the 
surface of microparticle accelerates anafyte binding and 
attainment of equilibrium, as a result the incubation time is 
diminished. The reactants bind irreversibly to the glass fibre 
matrix in the reaction cell. (Flore et al.，1988; Keller et al.，1991; 
IMx System Operation Manual, Abbot Laboratories) 
The reactants of MEIA assays are microparticles coated with 
a capture molecule which is antigen, antibody or analyte specific 
moiety, alkaline phosphatase-labelled conjugate, flurogenic 
substrate that is 4-methylumbellifetyl phosphate (4-MUP) and 
reaction cell which has a glass fibre matrix to which the immune 
complex binds. 
III.D.l.a. Reaction Process 
The reaction process of MEIA assay is illustrated in Figure 
III.1 (IMx System Operation Manual, Abbot Laboratories). Samples 
and microparticles were transferred to the incubation well of the 
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Figure III. 1: Reaction Process ofMcroparticIe Enzyme Immunoassay 
Tbe following is an illustration ofthe typical MEIAreaction process: 
1 ( + : _ ^ ^ 
> • : — 
Anti^ naIyteMk^ pa3tick S^ pk Antibody^ Antig,nCompkx 
^ ~ ~ ^ 
AUcdline Pho5phata5e ^P 
+ c J ^ —4 V - ^ 
c x \ 
y^""^”� 
Anti-AmIyte-S pedik Antibody^ Antigen Antibcdy CompleK 
Mk Phos Comug4te Capiured by the MEIA Raactian CeH 
Ghss FiberMatix ,、 ,, I 
. , T � � 一 y \ 广\ z ‘ + (^P) _ ^ " ^ 一 一 � + (MJ) 
� " y ^ ^ — W \ 
)^^mm^ ‘ 
^ ^ 
.,,丄1 , , ,,._ , Msfl^ dTurfceUiferane 
4-Metig^ nfceMetyi Antibody-Antigsnr 剛 is fluo««:e»t 
Pk«phate(MUP) ibitibcdyCotipfe. RkafMJp^SL 
isMesurad. 
MEIA schematic reactionsequence 
Source: Adapted from EVlx System Operation Manual, Abbot Laboratories 
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reaction cell. Analytes bounded to the microparticles to form an 
immune complex during the incubation period. An aliquot of the 
immune complex was transferred to the reaction that contains 
glass fibre matrix. After that, the immune complex binds 
irreversibly to the glass fibre matrix. The matrix was washed to 
remove unbound materials and the immune complex was retained 
by the glass fibre. Then, alkaline phosphatase-labelled conjugate 
was added to the matrix to form an ^antibody-analyte-conjugate 
sandwich”. Once again the matrix was washed. A fluorogenic 
substrate (4-MUP) was added. The hydrolysis of the 4-MUP to 
inorganic phosphatase and fluorescent 4-methylumbelliferone (4-
MU) is catalyzed by alkaline phosphatase conjugate. Finally, the 
MEL\ optical assembly measured the intensity of fluroescent light 
produced by 4-MU which is proportional to the concentration of 
the anal3^e. 
III.D. 1 .b. MEIA Optical Assembly 
A front-surface flurometer was used in the MEL\ optical 
assembly. Excitation energy was generated by mercuty arc lamp 
and then filtered to 365 nm to excite 4-MU molecules. 4-MU was 
excited to emits light at 448 nm. The 448 nm light generated was 
measured. The resulting light intenstiy was proportional to the 
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concentration of the analyte. Known concentrations of samples 
were measured to plot a calibration curve which is stored in the 
IMx system. As a result, unknown concentration can be calculated 
III.D. 1 .c. Operation 
Firstly, the operator put the appropriate assay software 
module in place. Then 24 reactions cells are loaded in a carousel. 
A minimum of 150 ,^1 of specimen, control sample or calibrator is 
added to the sample well of the reaction cell. The access door is 
opened, the carousel is then put into the analyzer and the reagent 
pack is placed into the reagent block. After the door is closed, one 
can start the assay by pressing the “run” button. After that, all 
steps are fully automated. 
III.D.2. AFP Assays 
III.D.2.a. AFP Reagents 
The reagents include IMx AFP reagent pack (No. 2257-20), 
IMx AFP mode 1 calibrator, IMx AFP calibrators (No. 2257-01)，IMx 
controls (No. 2257-10) and IMx AFP specimen diluent (No. 2257-
50). 
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The reagent pack (No. 2257-20) contains four bottles 
including: 
1. 1 bottle (4.5 ml) anti-AFP (mouse, monoclonal) coated 
microparticles in buffer with protein stabilizers. 
Preservative: sodium azide. 
2. 1 bottle (6.0 ml) anti-AFP (mouse, monoclonal): 
alkaline phosphatase conjugate in buffer with protein 
stabilizers. Preservatives: sodium azide and 
antimicrobial agents. 
3. 1 bottle (10 ml) 4-MUP, 1.2mM in buffer. Preservative: 
sodium azide. 
4. 1 bottle (16 ml) specimen diluent, buffered calf serum. 
Preservatives: sodium azide and antimicrobial agents. 
There is 1 bottle (4ml) IMx AFP (human) mode 1 calibrator 
(AFP prepared in buffered calf serum). Concentration: 50 ng/ml. 
Preservatives: sodium azide and antimicrobial agents. 
The IMx AFP (human) calibrators (No. 2257-01) include 6 
bottles (4 ml each) of concentrations of 0，15，50，100，200，350 
ng/ml. Preservatives: sodium azide and antimicrobial agents. 
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There are 3 bottles (4 ml each) of IMx AFP (human) controls 
(No. 2257-10), low (15-25 ng/ml), medium (64-96 ng/ml) and high 
controls (140-210 ng/ml). Preservatives: sodium and antimicrobial 
agents. 
There is 1 bottle (100 ml) IMx AFP specimen diluent (No. 
2257-50), buffered calf serum. Preservatives: sodium azide and 
antimicrobial agents. 
III.D.2.b. Sample Dilution 
When the result was greater than 350 ng/ml, the specimen 
should be diluted 3-fold with IMx AFP specimen diluent (No. 2257-
50) and reassayed. The result obtained should then be multiplied 
by3. 
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III.D.3. Total p-hCG Assay 
III.D.3.a. Total p-hCG Reagents 
The reagents include IMx total p-hCG reagent pack (No. 
lA06-20), IMx total p-hCG mode 1 calibrator, IMx total p-hCG 
calibrators (No. 1A06-01), IMx total P-hCG controls (No. 1A06-10) 
and IMx total P-hCG specimen diluent (No. lA06-50). 
The reagent pack contains 4 bottles including: 
1. 1 bottle (6.5 ml) anti_p_hCG (mouse, monoclonal) 
coated microparticles in buffer with protein stabilizers. 
Preservative: sodium azide. 
2. 1 bottle (6.5 ml) anti-3-hCG (goat, polyclonal): alkaline 
phosphatase conjugate in buffer with protein 
stabilizers. Preservative: sodium azide. 
3. 1 bottle (10 ml) 4-MUP, 1.2 mM in buffer. Preservative: 
sodium azide. 
4. 1 bottle (20 ml) specimen diluent in human serum 
nonreactive for HBsAg, anti-HCV and anti-HRM/HIV-
2. Preservative: sodium azide. 
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There is 1 bottle (4 ml) mode 1 calibrator with a 
concentration of 10 mIU/ml hCG in human serum nonreactive for 
HBsAg, anti-HCV and anti-HrV-l/HrV-2. Preservative: sodium 
azide. 
Six bottles (4 ml each) of IMx total p-hCG calibrators (No. 
1A06-01) are prepared in human serum nonreactive for HBsAg， 
anti-HCV and anti-HrV-l/HIV-2 at the concentration of 0, 10，75, 
250，500 and 1000 mIU/ml). Preservative: sodium azide. 
There are 3 bottles (4 ml each) of IMx total p-hCG controls 
(No.lA06-10) prepared in human serum nonreactive for HBsAg, 
anti-HCV and anti-HR^-l/HIV-2, including low control (25 
mIU/ml), medium control (150 mIU/ml) and high control (750 
mIU/ml). Preservative: sodium azide. 
There is 1 bottle (100 ml) of IMx total p-hCG specimen 
diluent (No. lA06-50) in animal and human serum nonreactive for 
HBsAg, anti-HCV and anti-HIV-l/HIV-2. Preservative: sodium 
azide. 
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III.D.3.b. Sample Dilution 
Because the concentration of total p-hCG in twin 
pregnancies is very high and is likely to exceed the upper limit of 
the test (1000 mIU/ml), the samples were diluted at 1:200 with 
IMx total p-hCG specimen diluent before assay. 
III.D.4. Intra- and Inter-assay Variation 
For evaluation of the intra-assay variation, the same sample 
was assayed 10 times within the same assay. Likewise, for 
evaluation of inter-assay variation, the sample was assayed in 10 
different assays. The mean and the standard deviation (SD) of 
optical density (OD) of both high and low range samples were 
calculated. The co-efficients of variation (CV) within and between 
assays were calculated according to the formula CV = SD (OD) / 
mean (OD). The results of the intra-assay and inter-assay variation 
of AFP and total p-hCG assay are shown in Tables III.A and III.B 
respectively. 
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Table m.A: Intra- and Inter-assay Variation ofAFP Assay 
Inter-assay Intra-assay 
OD (LC” OD (HC)# OD (LC)* OD (HC)# 
T ^ 1047.6 206.4 I o 4 ^ 
r ^ 1051.0 r ^ 96h7 
209.6 1025.2 202.9 9 ^ 
m 9 98M ri3A I20^ 
i ^ i ^ i l 1 ^ ~ 9357 
i ^ 1057.7 1 ^ 974.0 
r ^ 1183.4 r ^ if02^ 
2 ^ 1113.8 201.9 F09l9 
WT3 1029.6 20H I M 1 
m l 1144.9 r ^ i o ^ 
Mean 190.1 1063.0 191.8 l029.4 
S.D. u2 648 TI9 773 
C.V. 6.61% 6.09% 6.730/0 7lT% 
*LC denotes lowest concentration. 
枯 
HCdenotes highest concentration. 
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Table m.B: Intra- and Inter-assay Variation oftotal p-hCG Assay 
Inter-assay Intra-assay 
OD (LC)* OD (HCf OD (LC)* OD (HCf 
88.1 934.0 8^0 9 ^ 
86.9 966.4 7 ^ 9 f [ 2 
^ 1008.8 ^ W L 2 
96.8 916.9 ^ r07L9 
^ 9 ^ Fool T ^ ^ 
887 1089.6 m 3 l 0 4 ^ 
81.3 961.3 i08^ 833.4 
Wl Wj i ^ B 9 ^ 
83.5 1009.0 i 0 ^ 9 0 ^ 
^ 1039.3 K e ^ 
Mean ^ 976.47 ^ 9 ^ 
^ 5 J ~ 58^ 9 ^ ^ 
CV. 6.56% 6.03% 9 ^ 0 T6Wo 
J _J 
* LC denotes lowest concentration. 
# 
HC denotes highest concentraton. 
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III.E. Data Handling 
The biochemical results and clinical information were 
entered into a 486 personal computer using Excel (5.0). 
III.F. Statistical Analysis 
III.F.1. Calculations of Median Values of Maternal Serum 
Alpha-fetoprotein and Human Chorionic 
Gonadotrophin Concentrations 
The median values of alpha-fetoprotein and human 
chorionic gonadotrophin were calculated for each gestational 
week. Multiples of the medians are used worldwide in this area of 
research. Therefore the alpha-fetoprotein and human chorionic 
gonadotrophin concentrations were expressed as multiples of the 
median so that we can compare with previous publications. 
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III.F.2. Analysis for Adverse Outcomes or Complications 
The ability of using AFP and hCG to predict adverse 
pregnancy outcomes or complications were analyzed by receiver 
operating characteristic (ROC) curve. ROC curve was originally 
developed for electronic signal detection (Green and Swets, 1966). 
In medical field, it is used to assess the accuracy of a test and can 
be used to compare the accuracy between two tests. 
The performance of a test is best described by its sensitivity 
and specificity. Sensitivity is the ability of a test to correctly 
identify cases with a condition, while specificity is the ability of a 
test to correctly identify the cases without a condition. Sensitivity 
and specificity are inter-related. It follows that the performance of 
a test depends on the choice of cut off point. (Fig III.2). Therefore, 
the characteristics of a test is best described by the ROC curve, so 
that one can choose the most appropriate cut off point based on 
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Figure HI.2 Receiver operating characteristic curve ofTest 
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one's requirement. 
A good screening test should ideally have high sensitivity 
and specificity and a receiver operating characteristic curve of 
bending to the left and upwards (area under curve > 0.5)，as curve 
A in Figure III.1. A poor screening test as curve B shown in Figure 
III. 1 has a receiver operating characteristic curve approaching the 
diagonal (curve C) of the graph (area under curve = 0.5). The larger 
the area under receiver operating characteristic curve, the more 
accurate the test is. 
The area under curve of the test was compared with the line 
ofno accuracy (area = 0.5) (Hanley and McNeil, 1982). The areas 
under curve between different tests were compared with each 
other using DeLong statistics (DeLong et al, 1988). p less than 
0.05 was regarded as statistically significant. 
To avoid errors in analysis due to effect of repeated 
sampling, the results of maternal serum alpha-fetoprotein and 
human chorionic gonadotrophin in multiples of the median (MoM) 
were grouped in 2-weekly interval because blood was taken at a 2 
weekly intervals in each subject. 
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IILF.3. Adjustment of Alpha-fetoprotein and Human 
Chorionic Gonadotrophin for Gestational Age and 
Maternal Weight 
The matemal serum alpha-fetoprotein and human chorionic 
gonadotrophin concentration is dependent on gestational age and 
matemal weight as explained in the previous section. 
Transformation of raw data to MoM enables us to correct for 
gestational dependency. However, it is extremely difficult to correct 
for matemal weight using this transformation. 
It is well known that most biological parameters follow 
exponential distribution, which can be transformed to a linear 
relationship by natural logarithm transformation. Natural 
logarithmic transformation of AFP and hCG concentration of the 
raw data were confirmed to have linear relationship with 
gestational age. Thereafter, a multiple linear regression model is 
generated for each hormone so that an expected value of AFP and 
hCG corrected for gestational age and matemal weight could be 
calculated. The ratio of the difference between the expected and 
the true value of ln(AFP) or ln(hCG) divided by the standard 
deviation of the residual is a measure of how much the true 
hormonal level deviate from the standard. I termed these ratios as 
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AFPi or hCGi accordingly. With these new values, analysis by ROC 
curve was repeated to demonstrate whether the accuracy of the 




From September 1994 to September 1996, 119 women with 
twin pregnancies between 14-24 weeks of gestation were recruited 
for the study. The characteristics of these patients are shown in 
Table W.A, The age of the patients at the expected date of delivety 
ranged from 19 to 40 years. The maternal weight at sampling 
ranged from 42 to 100.2 kg. The birthweight of twins ranged from 
0.59 to 3.45 kg. As blood samples were obtained at 2-weekly 
intervals, series of samples were collected for each patient. The 
incidences of the adverse outcomes are shown in Table IV.B. 
IV.A. Median Values of Matemal Serum Alpha-fetoprotein and 
Human Chorionic Gonadotrophin 
The distribution of maternal serum alpha-fetoprotein 
(MSAFP) (ng/ml) and human chorionic gonadotrophin (hCG) 
(IU/ml) concentrations throughout mid-trimester is shown in 
Figure W.1 and r^.2. Table IV.C and W.C lists the median values 
of MSAFP and hCG in singleton and twin pregnancies according to 
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Table rV.A: Patient characteristics ofrecruited cases 
Mean 土 S.D. 
Age (years) 31.65±4.52 
Maternal Weight (kg) 59.25 ± 9.69 
Birthweight of Twins (kg) 2.35±0.57 
Onset of Labour Number ofCases % 
Spontaneous 55 46.2 
Induced 37 JI7i 
Elective Caesarean Section 27 22.7 
Total U9 i^ 
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Table IV.B: Incidence of adverse outcomes 
Outcomes Number ofCases % 
Preterm (<37 weeks) 50 42 
Spontaneous Preterm (<37 weeks) 32 26.9 
Premature (<34 weeks) f6 IJ4 
Spontaneous Premature (<34 weeks) U ^ 
Low birthweight 70 53.8 
Pregnancy induced hypertension 10 ~ 8^ 
Growth discordant 21 f76 
Fetal death 6 5 
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Figure IV.1 Distribution ofMSAFP during midtrimester 
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race. The Caucasian singleton and twin median values of alpha-
fetoprotein were extracted from the publication of Ghosh and 
associates (1982). and the Caucasian singleton and median values 
of hCG were extracted from the reports of Nebiolo and colleagues 
(1991). Two articles were chosen because both singleton and twin 
median values of AFP and hCG are presented while in other 
publications the singleton median values was not displayed. On 
the other hand, the Chinese twin median values are the results of 
current study, while data for singleton pregnancies were based on 
a biochemical screening program for Down's syndrome in the same 
institute. There was a consistent pattem of difference in the 
concentration of both hormones across gestational age according 
to ethnic origins. Among Chinese twin pregnancies, both AFP and 
hCG concentrations were about twice the concentration observed 
in singleton pregnancies of the same gestation in the second 
trimester. 
The raw data for singleton and twin pregnancies were 
compared with Mann-Whitney test (Table IV.C and Table IV.D). 
Matemal serum alpha-fetoprotein and human chorionic 
gonadotrophin concentrations was significantly higher than that of 
singleton in all gestations assessed (p <0.05). 
To give better visual account of the changes of alpha-
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fetoprotein and human chorionic gonadotrophin with gestational 
age, I illustrates the changes in Figure IV.3 and IV.4 which show 
singleton and twin medians of matemal serum alpha-fetoprotein 
and human chorionic gonadotrophin in Chinese and Caucasian 
(Ghosh et al” 1982; Nebiolo et al, 1991). Both medians of 
matemal serum alpha-fetoprotein and human chorionic 
gonadotrophin among Chinese are obviously higher than those of 
Caucasian for each gestational week, in both singleton and twin 
pregnancies. However, a formal statistically comparison was not 
done because the raw data of the Caucasian population were not 
available. 
My result shows that if matemal serum alpha-fetoprotein 
(MSAFP) or human chorionic gonadotrophin (MShCG) 
concentration is greater than 2 multiples of the median (MoM), 
almost all patients have adverse pregnancy outcomes or 
complications. The outcomes or complications of the patients with 
1 or more samples with MSAFP higher than 2 MoM or MShCG 
concentration higher than 2 MoM are shown in Table rV^ .E and 
were analyzed with chi-square test or fisher's exact test where 
appropriate. Statistically signficant was defined as p < 0.05. 
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Figure W.3 MSAFP median values during mid-trimester 
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Figure W.4 MShCG median values during mid-trimester 
160 1 
\ 1 1 4 0 - \ 
12�\ 
! : : V 
4 � ^ ^ ^ ^ ^ ^ ^ ^ " ^ ^ 
20- ^ ^ ^ r " 
0 ^ ‘ ‘ 1 1 r ~ I — — , — — , — — , — — , — — � — — 
13 1 4 15 1 6 1 7 18 1 9 2 0 2 1 2 2 2 3 2 4 2 5 
Gestational Week 
~ ^ Caucasian Singleton ~»~ Caucasian Twin 
~*~ Chinese Singleton -^c- Chinese Twin 
58 
Table W.E: Pregnancy complications and adverse outcomes in patients with 
MSAFP or MShCG > 2MoM 
Problem ~ ~ O v e r a l l ~ MSAFP > 2MoM MShCG > 2MoM 
incidence incidence p incidence ^ 
( % ) r/o) a^ 
preterm (<37 42 87.5 0.01 52.6 ~ ~ N S ~ 
weeks) 
spontaneous ^ ^ ^ J ^ J；^  
preterm (<37 
weeks) 
premature (<34 iJ4 50 0 ^ 2 U NS 
weeks) 
spontaneous ^ W1 ^ I J i J；^  
premature (<34 
weeks 
^ ^ T^5 i ^ 1 ^ NS~~ 
growth V7^ ^ NS 2 ^ ^ ~ ~ 
discordant 
LBW 59.3 Ys NS ^ N S ~ ~ 
fetaI death 5.1 ^ NS i ^ l NS~~~ 
P < 0.05 was regarded as statistically significant. 
NS; not significant 
� ^ 
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IV.B. Prediction of Adverse Outcomes by Matemal Serum 
Alpha-fetoprotein and Human Chorionic 
Gonadotrophin 
The intrinsic accuracy of maternal serum alpha-fetoprotein 
and human chorionic gonadotrophin (multiples of median or MoM) 
prediction for adverse outcomes was analyzed by receiver 
operating characteristic (ROC) curve (Hanley and McNeil, 1982). 
IV.B. 1 • Preterm Delivety 
Figure IV.5 and W,6 illustrates the receiver operating 
characteristic (ROC) curve of maternal serum alpha-fetoprotein 
(MSAFP) (MoM) and human chorionic gonadotrophin (hCG) (MoM) 
screening for preterm delivety (<37 weeks) respectively. Samples 
were grouped at 2-weekly intervals. Only those curves with 
significant difference (p<0.05) from the line of no accuracy (Area of 
0.5) were plotted. Matemal serum alpha-fetoprotein taken at 18-
19，20-21, 22-23 and 24 weeks and human chorionic 
gonadotrophin assessed at 18-19 and 24 weeks can predict 
preterm delive^ (Table R .^F). By DeLong's method (DeLong et al.， 
1988)，there is no significant difference between these curves 
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Figure TV.5 ROC curve ofusing MSAFP to screen for 
preterm deliveries (<37 weeks) 
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Figure TV.10 ROC curve ofusing MShCG to screen for 
spontaneous premature deliveries (<34 weeks) 
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Table W.F: MSAFP and hCG screening for preterm deliveries (<37 weeks) 
Gestational ~~ AFP ~ | ^ ^ 
Weck ~ ~ ^ ~ ~ p A；；^~~ p 
1^5 ^ ^^ S ^ J ^ ~ " 
~ ~ ^ ^ ^ 5^ 515 J ^ s ~ 
^ ^ ^ 5：^ 5 ^ ~ ~ 
^ ^ ^ ^ ^ ~ " 
22-23 ~ ~ ^ ^ 0 ^ J；^^ 
^ ^ 5 ^ ^ ^ ~ ~ 
NS: not significant 
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although the area under curve of using AFP at 24 week to predict 
preterm delivety is the largest. 
IV.B.2 Spontaneous Onset Preterm Delivety 
Preterm delivery (<37 weeks) with spontaneous onset of 
labour was treated as a separate outcome. Figure IV.7 and IV.8 
presents the receiver operating characteristic (ROC) curves of 
using alpha-fetoprotein and human chorionic gonadotrophin to 
screen for spontaneous preterm deliveries. Only the area under 
curve with significant difference from the area of no accuracy (0.5) 
would be constructed. Table IV.G lists the p value and area under 
curve of alpha-fetoprotein and human chorionic gonadotrophin 
sampled at different gestational age as a screening test for preterm 
delivery with spontaneous onset of labour at different gestation. 
There are no significant differences among the areas under curves 
of these weeks (both alpha-fetoprotein and human chorionic 
gonadotrophin screening). 
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Figure TV.10 ROC curve ofusing MShCG to screen for 
spontaneous premature deliveries (<34 weeks) 
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Figure TV.10 ROC curve ofusing MShCG to screen for 
spontaneous premature deliveries (<34 weeks) 
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Table W.G: MSAFP & hCG screening for spontaneous preterm delivery 
(<37 weeks) 
Gestational "" AFP h C G ~ 
Week Area under Curve p Area under Curve p 
14-15 ^ NS K ^ ^ ^ 
^ ^ ^ NS ^ 5；^  
^ ^ ^ ^ ^ ~ 
^ ^ 002 Ksi ^^ § 
22-23 ^ T^ ^ ^ ~ " 
24 ~ ~ ~ ~ ^ ^ 0 ^ j;^ § 
NS: not significant 
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IV.B.3. Premature Delivery 
Matemal serum alpha-fetoprotein is not significantly related 
to premature delivety before 34 weeks. Figure IV.9 shows the 
receiver operating characteristic (ROC) curve of human chorionic 
gonadotrophin (MoM) prediction for premature delivety. Again, the 
graph shows only those curves of the weeks of sampling with 
significant difference (p<0.05) from the line ofno accuracy (area of 
0.5). The p value and area under curve are presented in Table 
IV.H. Matemal serum human chorionic gonadotrophin screening 
at 16-17 week (p=0.03) and 24 week O9=O.OO) is predictive for 
premature delivety. There are no significant differences among 
areas under curves of these weeks with DeLong's method (DeLong 
et al, 1988). Nonetheless, human chorionic gonadotrophin 
sampling at 24 week has the largest area under curve. 
IV.B.4. Spontaneous Premature Delivety 
Premature delivety (<34 week) with spontaneous onset of 
labour was treated as a separate outcome parameter. Figure IV.10 
shows the receiver operating characteristic (ROC) curve of using 
matemal serum alpha-fetoprotein (MSAFP) and human chorionic 
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Figure TV.10 ROC curve ofusing MShCG to screen for 
spontaneous premature deliveries (<34 weeks) 
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h b l e W.H: MSAFP & hCG screening for premature delivery (<34 weeks) 
Gestational AFP ‘ 1 hCG 
Week ~ ^ ~ ~ " —p A^^~" —p 
I4H5 0¾ 5^ ^ 5^ 
^ 0 5 3 5 ^ 0 ^ ^ 2 
^ ^ NS ^ ;^j^  
^ 0 ^ NS ^ J ^ 
2^ ^ 5；^§ ^ ^ 
24 ^ NS 0 ^ 5 ^ ~ ~ 
NS: not significant 
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Figure TV.10 ROC curve ofusing MShCG to screen for 
spontaneous premature deliveries (<34 weeks) 
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gonadotrophin (hCG) to predict spontaneous onset premature 
delivety. Once again, only the curves of samples of the weeks with 
significant difference from the line of no accuracy (area of 0.5) 
were plotted. By receiver operating characteristic curve analysis, 
alpha-fetoprotein screening does not predict spontaneous 
premature delivery. Table IV.I summarizes the p value and area 
under curve of alpha-fetoprotein and human chorionic 
gonadotrophin screening for premature delive^ with spontaneous 
onset of labour at different gestation. There are no significant 
differences among the areas under curves of these curves. 
rV.B.5. Other Outcomes or Complications 
Only samples taken at 22-23 week can maternal serum 
alpha-fetoprotein (MoM) predict pregnancy induced hypertension 
(PIH) (area under curve = 0.71, p=0.00). Growth discordant can 
only be predicted by alpha-fetoprotein screening and only at 22-23 
week (Area under curve = 0.64, p=0.03). By receiver operating 
characteristic curve analysis, maternal serum alpha-fetoprotein or 
human chorionic gonadotrophin is not significantly related to low 
birth weight infants and fetal death. 
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TTaWe W.I: MSAFP & hCG screening for spontaneous premature delivery 
(<34 weeks) 
Gestational — AFP ‘ j^^^ 
鬚 ~ ^ ~ ~p x ^ ~ ~ — ； — 
^ ^ NS ^ ;^¾ 
16_17 ^ NS ^ 5；^§ 
^ ^ ^ 0 ^ 5： ^ ~ " 
^ ^ NS 5:ii - ^ 
22-23 ^ ^ ^ 5；^^ 
^ 0 ^ NS ^ ^ 
NS: not significant 
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IV.B.6. Single Predictor for Most Adverse Outcomes 
As a single analyte to screen for most adverse outcomes, 
alpha-fetoprotein (MoM) taken at 22-23 week appear to be the best 
one. Maternal serum alpha-fetoprotein screening at 22-23 week 
can predict preterm delivety, pregnancy induced hypertension 
(PIH) and growth discordant. Figure n/.l l illustrates the receiver 
operating characteristic (ROC) curve of matemal serum alpha-
fetoprotein screening at 22-23 week. 
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Figure W . n ROC curve ofusing MSAFP to screen for 
adverse outcomes at 22-23 week 
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IV.C.Adjustment of Maternal Serum Alpha-fetoprotein 
and Human Chorionic Gonadotrophin for Matemal 
Weight and Gestational Age 
n^C.l. Distribution of Alpha-fetoprotein and Human 
Chorionic Gonadotrophin during Mid-trimester 
Figure IV.1 and IV.2 present the distribution of matemal 
serum alpha-fetoprotein and total beta-human chorionic 
gonadotrophin concentration during mid-trimester. Alpha-
fetoprotein (AFP) concentration increases exponentially as the 
gestational age advances during mid-trimester while human 
chorionic gonadotrophin (hCG) declines rapidly in early mid-
trimester and reach to a plateau in late mid-trimester. The 
distributions of both hormones in each gestational week are 
skewed. By natural logarithm transformation, we can change them 
into linear relations (Figure W.12 and IV.13). Figures 
76 
Figure IV.12 Variation ofIn(AFP) with gestational age 
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IV.12 and IV.13 show that ln(AFP) increases and ln(hCG) 
decreases with gestational age. Both figures show a linear relation. 
n^.C.2. Adjustment of Alpha-fetoprotein for Maternal Weight 
and Gestational Age 
Although ln(AFP) is not significantly related to maternal 
weight (r=0.06, p=0.28), multiple regression analysis shows that 
both gestational age (p=0.00) and maternal weight (p=0.00) are 
significantly related to ln(AFP), as depicted in the following 
equation: 
Ideal ln(AFP) = 2.40 - 0.01 (MW) + 0.16 (GA) 
where MW represents maternal weight at sampling, GA represents 
gestational age at sampling. 
A new value denoted by AFPi which is a ratio calculated as 
the difference between expected and true values of ln(AFP) divided 
by the standard deviation of the residual: 
(Actual ln(AFP) 一 Ideal ln(AFP))/S.D. 
where S.D. is the standard deviation of the residual. 
AFPi should be independent of gestational age and maternal 
weight. 
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Figure rV .^14 and Figure W.15 show the scatterplot ofAFPi 
according to gestational age and matemal weight respectively. It 
confirms that AFPi is independent of gestational age and maternal 
weight (for AFPi and gestational age, correlation coefficiency r = 
0.00 and slope of regression line = 0.00; and for AFPi and 
maternal weight, r = 0.00 and slope = 0.00). 
IV.C.3. Adjustment of Human Chorionic Gonadotrophin for 
Matemal Weight and Gestational Age 
In contrast to alpha-fetoprotein, maternal serum human 
chorionic gonadotrophin concentration is significantly related to 
matemal weight (r=-0.25, p=0.00). By multiple regression analysis, 
ln(hCG) has also shown to be significantly related to gestational 
age (p=0.00) and matemal weight (p=0.00) and the following 
equation was derived: 
Ideal ln(hCG) = 6.38 - 0.01(MW) - 0.09 (GA) 
Where MW denotes maternal weight at sampling and GA denotes 
gestational age at sampling. 
A new value, hCGi, is derived similar to AFPi by the 
following equation: 
((Actual ln(hCG) - Ideal ln(hCG) )/S.D. 
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Figure TVA3 Variation ofln(hCG) with gestational age 
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Figure TV.15 Variation ofAFPi with maternal weight 
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where S.D. is the standard deviation ofthe residual. 
Figure IV.16 and Figure IV.17 confirm that hCGi is 
independent of both gestational age and matemal weight (for both 
graph, correlation coeficiency r = 0.00，slope of regression line = 
0.00). 
IV.D.Predictiveness of Alpha-fetoprotein and Human 
Chorionic Gonadotrophin for Adverse Outcomes 
After Adjusted for Matemal Weight and Gestational 
Age 
The predictiveness of AFPi and hCGi, which are maternal 
weight and gestational age independent, was analyzed by receiver 
operating characteristic (ROC) curve (Hanley and McNeil, 1982). 
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Figure TVA3 Variation ofln(hCG) with gestational age 
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IV.D. 1 • Preterm delivety 
The receiver operating characteristic (ROC) curves of 
samples taken at 18-19 week, 20-21 week, 22-23 week and 24 
week for AFPi screening for preterm delivety (<37 week) are 
significantly different from the line with no accuracy (area of 0.5) 
and the ROC curve of hCGi screening for preterm delivey is only 
predictive at 24 week (Table W.J). Figure W.18 and W.19 illustrate 
the ROC curves of AFPi and hCGi screening for preterm delivety. 
Only the curves with significant different from the line of no 
accuracy (area of 0.5) were constructed. There are no significant 
differences among the areas under curves of these tests (DeLong et 
a/.，1988). The area under curve of AFPi screening at 24 week is 
the largest among those with significant different from the line of 
no accuracy (area of0.5). 
r/.D.2. Spontaneous Preterm Delivety 
Figure IV.20 and IV.21 shows the receiver operating 
characteristic (ROC) curves of AFPi and hCGi screening for 
spontaneous preterm delivety (<37 week). Only curves of the 
weeks with significant difference from the line of no accuracy (area 
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Figure TV.lS ROC curve of using AFPi to screen for 
preterm deliveries (<37 weeks) 
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Figure TV.19 ROC curve ofusing hCGi to screen for 
preterm deliveries (<37 weeks) 
:il~~~~7^  
0 7 y ^ 
.安06 r / 
:卜 y z 
\f 
0 . 1 — j ^ 
O J ^ — — ‘ — — . — — I — — I — — I — — , — — , — — , _ 




TablerV.J: AFPi and hCGi screening for preterm deliveries (<37 weeks) 
Gestational AFPi~~ F h ^ 
Week ~~~Area ； Area p 
14-15 0 ^ NS ^ ~NS 
i ^ 0 ^ NS ^ NS 
18-19 0 ^ ^ ^ ^ 
20-21 0 ^ ^ o l 6 NS 
一 22-23 ^ 0 ^ 0 ^ NS 
24 ~ ~ W l ^ 0 ^ ^ ~ ~ 
NS: not significant 
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Figure JV.20 ROC curve ofusing AFPi to screen for 
spontaneous preterm deliveries (<37 weeks) 
0.9- / , : : . . " " " C ^ ^ | ! ; ^ _ 
� 7 ^ / 
f � 6 f / 
1 � 5 / • Z 
“ 0 . 4 / X 
:i^ 
0 * ^ — — I — — 1 — — . — — . — — , — — , , — — , — — 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 
l-specif1city 
‘• • - -18-19 week ~~•~ 24 week 
90 
Figure rV.21 ROC curve ofusing hCGi to screen for 
spontaneous preterm deliveries (<37 weeks) 
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of0.5) were constructed. There is no significant difference between 
these curves. From table W.K the area under curve of AFPi 
screening at 24 week is the greatest. 
rV.D.3. Premature Delivety 
By ROC curve analysis, AFPi screening cannot predict 
premature delivety (<34 weeks) whereas hCGi screening can 
predict premature delivety at 14-15 week, 16-17 week and 24 
week (Table IV.L). Figure IV.22 presents the receiver operating 
characteristic (ROC) curve of hCGi screening for premature 
delivety. 
rv.D.4. Spontaneous Premature Delivety 
By receiver operating characteristic curve (ROC) analysis, 
AFPi cannot predict premature delivety (<34 week) with 
spontaneous onset whereas hCGi can predict it. Figure IV.23 
illustrates the receiver operating characteristic (ROC) curves of 
hCGi screening. Only those curves with significant difference from 
the line of no accuracy (area of 0.5). From Table W.M, the area 
under curve of hCGi screening at 18-19 week is the largest. 
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Table TV.K: AFPi and hCGi screening for spontaneous preterm deliveries 
(<37 weeks) 
~ ~ G e s t a t i o n a l ~ AFPi ~ h ^ 
Week Area p value Area p value 
14-15 0 J 9 NS ^ i i NS 
1 6 ^ 0 ^ NS 0 ^ ^ 
i ^ ^ ^ ^ ^ 
20-21 0 ^ NS ~ ~ ^ ^ 
22-23 0 l 7 NS 0 ^ 0 ^ 
24 ^ 000 ^ NS 
NS: not significant 
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Figure TV.L: AFPi and hCGi screening for premature delivery (<34 weeks) 
Gestational AFPi hCGi 
Week Area ^ Area p 
14-15 ^ NS 0 ^ 0 ^ 
16-17 ^ NS 0 ^ ^ 
18-19 0 ^ N^ ^ NS 
20-21 0 ^ NS 0 J 8 NS 
22-23 ^ NS ^ NS 
U 0 ^ NS ^ 0 ^ 
NS: not significant 
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Figure TV.22 ROC curve ofusing hCGi to screen for 
premature deliveries (<34 weeks) 
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Figure TV.23 ROC curve ofusing hCGi to screen for 
spontaneous premature deliveries before 34 weeks 
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TaWe jy.M: AFPi and hCGi screening for spontaneous premature deliveries 
(<34 weeks) 
Gestational AFPi V hCGi 
Week ~ A i ；^ ^ ~ p A i ^ ~ ^ 
14-15 ~ ~ ~ ^ 5^ ^ ^ ~ 
16-17 ~ 0 ^ NS ^ j;j^  
i ^ ^ NS oTi 0 ^ ~ 
20-21 ^ ~NS ^ NS 
22-23 0 l 3 NS ^ ^ 
24 ^ NS 069 0 0 2 ~ 
NS: not significant 
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IV.D.5 Other Adverse Outcomes or Complications 
Pregnancy induced hypertension and growth discordance 
can only be predicted by AFPi and only at 22-23 week. AFPi or 
hCGi is not significantly associated with low birth weight infants 
and fetal death. 
r^.D.6 Single Predictor for Most Adverse Outcomes 
AFPi at 22-23 weeks, which is independent of maternal 
weight and gestational age, still predicts most outcomes. AFPi 
screening can predict preterm delive^ before 37 weeks (area 
under curve = 0,66，p=0.01), pregnancy induced hypertension 
(area under curve = 0.75, p=0.00) and growth discordant (area 
under curve = 0.65, p=0.03). Figure IV.24 presents the receiver 
operating characteristic (ROC) curve of AFPi screening for the 
above three adverse outcomes at 22-23 week. 
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Figure TV.24 ROC curve ofusing AFPi to screen for 
adverse outcomes at 22-23 weeks 
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V.A. Median Values of Matemal Serum Alpha-fetoprotein 
and Human Chorionic Gonadotrophin 
Dating according to menstrual histoty is not reliable. Firstly, 
the last menstrual date may not be accurately remembered. 
Secondly, the menstrual cycles may be irregular. Thirdly, the exact 
time of ovulation and fertilization may be variable. Therefore, it is 
important to confirm the menstrual date by ultrasound 
examination. In many previous studies, gestational ages were not 
routinely confirmed by ultrasound examination. In my study, all 
cases were confirmed by ultrasound scanning. Gestational age is 
the most important factor influencing the alpha-fetoprotein and 
human chorionic gonadotrophin concentration. Therefore, the use 
of an ultrasound estimation of gestational age before blood 
collection for measurement of alpha-fetoprotein and human 
chorionic gonadotrophin concentration optimizes the accuracy of 
the screening test because the median values were calculated 
according to the gestational age. 
100 
Our results confirm that matemal serum alpha-fetoprotein 
and human chorionic gonadotrophin concentrations in twin 
pregnancies are higher than those in singleton pregnancies in 
Chinese. This finding is in agreement with other studies in 
Caucasian (Ghosh et al, 1982; Wald et al.，1991; Spencer et al.， 
1994; Bamabei et aL, 1995; Canick et al.，1990; Nebiolo et al.， 
1991). 
The increase in matemal serum alpha-fetoprotein 
concentration in twin pregnancies can be explained by the 
increased production of alpha-fetoprotein by two fetuses and the 
increased passage of alpha-fetoprotein from fetal to matemal 
circulation through increased utero-placental interface. In 
addition, the larger surface area of the twin gestational sac (or 
sacs) also contributes to the increase in transmembranous 
transfer. The larger placental size and more human chorionic 
gonadotrophin production can explain the increase in human 
chorionic gonadotrophin concentration in twin pregnancies. 
My findings also show that both alpha-fetoprotein and 
human chorionic gonadotrophin in Chinese are higher than those 
in Caucasian (Ghosh et al, 1982; Nebiolo etal, 1991). This finding 
is in accordance with previous studies in which the median values 
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of matemal serum alpha-fetoprotein and human chorionic 
gonadotrophin in Asian were compared with Caucasian (OBrien et 
al.，1993; Muller et al, 1994; OBrien etal., 1997). 
This ethnic difference may be partly explained by the fact 
that Caucasian has larger matemal weight which is negatively 
associated with alpha-fetoprotein and human chorionic 
gonadotrophin concentration, as shown in our study. As a result 
Caucasian has lower maternal serum alpha-fetoprotein and 
human chorionic gonadotrophin concentrations. However, 
matemal weight alone cannot fully explain the fact that both 
hormones concentrations in Chinese are almost double those in 
Caucasian. Secondly, the difference may be due to laboratoty error 
in hormonal assay. With modem automated laboratory method, it 
is unlikely that such a great difference could be attributed to inter-
laboratoty error. Therefore the difference probably represent a true 
racial difference. 
In conclusion, appropriate normogram for matemal serum 
alpha-fetoprotein and human chorionic gonadotrophin should be 
used in patients of different ethnicity. 
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V.B. Matemal Serum Alpha-fetoprotein and Human 
Chorionic Gonadotrophin Screening for Adverse 
Outcomes 
By chi-square or Fisher's exact test (where appropriate), my 
results confirmed previous reports that pregnancies with elevated 
MSAFP (> 2 MoM) are associated with a high risk incidence of 
pregnancy complication. However, those with elevated MShCG ( > 
2 MoM) are not associated with adverse outcomes. By ROC curve 
analysis, I found that elevated MShCG is associated with adverse 
pregnancy outcomes in certain periods. This might have been due 
to inadequate sample size for univariate analysis, or the cutoff of 2 
MoM for univariate analysis was not the optimal one. 
The receiver operating characteristic (ROC) curve 
summarizes the intrinsic accuracy of a screening test and from the 
curve we can choose a cutoff point based on the sensitivity and 
specificity of the test. Furthermore, the difference in performance 
of two or more screening test can be compared using the DeLong 
statistics (DeLong et al, 1988). The area under curve may give us 
hint how to choose a screening test by looking for one with the 
larger area. 
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Twin pregnancies have a higher rate of preterm delivery (<37 
week) than singleton pregnancies (Ho and Wu, 1975) and higher 
mortality (Medearis et al, 1979; Flowler et al, 1991). Thus, it 
would be clinically important if we can screen for pregnancies at 
higher risk of preterm deliveries so that we can provide greater 
antenatal surveillance. 
My result showed that matemal serum alpha-fetoprotein 
screening at 18-24 week and human chorionic gonadotrophin 
screening at 18-19 and 24 week could predict preterm delivety 
whereas it appears that samples taken at 24 week tested for 
serum alpha-fetoprotein had the greatest area under curve. This 
suggests that matemal serum alpha-fetoprotein screening at 24 
week may be a better time although the difference is not 
significant. 
This may be due to the fact that the detection of the 
difference in area requires a much substantiate sample. As the 
twin birth rate is not high, it is difficult to achieve an adequate 
sample size for the detection of the difference between different 
screening tests. The origins of preterm birth may be spontaneous 
or iatrogenic as a result of a medical decision that delivety is 
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essential for matemal or fetal reasons. Therefore I analyzed the 
cases of preterm delivery with spontaneous onset of labour as a 
separate parameter of adverse outcomes. 
After this restriction, maternal serum alpha-fetoprotein 
screening is predictive for preterm delivery only at 18-21 week and 
24 week whereas human chorionic gonadotrophin screening can 
screen at 18-19 and 22-23 week. Alpha-fetoprotein screening at 24 
week still has the greatest area. From the Figure IV.5, the turning 
points may be chosen as the cutoffs for the test and for alpha-
fetoprotein screening at 24 week and the corresponding sensitivity 
and specificity of the cutoffs are (33.3% and 94.4%), or (38.1% 
and 88.9%), or (57.1% and 75%) or (81% and 55.6%). From Figure 
IV.7, the tuming points of the curve for alpha-fetoprotein 
prediction at 24 week for spontaneous preterm deliveries have the 
sensitivity and specificity of (6.7% and 100%) or (40% and 92.9%) 
or (66.7% and 73.8%) or (86.7% and 54.8%). 
Although preterm delivety is defined as birth before 37 
completed weeks ofgestation (Thom et al, 1984; Walker and Patel, 
1986; Preterious et al, 1993), it is well known that infants bom 
before 34 weeks have higher complications (i.e. hyaline membrane 
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disease) from those born between 34-37 weeks and have higher 
mortality. It is therefore more important to identify those 
pregnancies delivered at before 34 weeks, for which I define as 
premature deliveries (Hong et al.，1996). 
I found that maternal serum human chorionic 
gonadotrophin is significantly associated with premature delivety 
at 16-17 week and 24 week. Twenty four week appears to be a 
better time for the screening test. For those with spontaneous 
onset of labour, maternal serum human chorionic gonadotrophin 
is significantly associated with premature delivety at 18-19 week 
and 24 week (Table W.l). The best timing for this screening 
appears to be 18-19 week. The cutoffs of the test at 24 week to 
predict premature deliveries could be with the sensitivities and 
specificities of (2.22% and 96%) or (44.4% and 84%) or (66.7% 
and 68%) or (88.9% and 50%) (Figure IV.9) whereas the cutoffs of 
the test at 18-19 week predicting spontaneous premature 
deliveries could have the sensitivities and specificities of (12.5% 
and 96.6%) or (25% and 82.8%) or (62.5% and 67.2%) or (100% 
and 51.7%) (Figure RMO). 
106 
Despite modem antenatal care, pre-eclampsia is a leading 
cause of maternal and infantile morbidity and mortality. This 
disease lacks a good screening test for early detection. It has been 
reported that aspirin may reduce the incidence or severity of 
pregnancy induced hypertension (Beaufils et al.，1985; McParland 
et al, 1990; Uzan et al, 1991; Robertson et al” 1976.) If a good 
screening test is available, we may be able to offer better care to 
the high risk group. Our result indicates that matemal serum 
alpha-fetoprotein screening at 22-23 week is significantly related 
to pregnancy induced hypertension (PIH). From Figure rv.ll，the 
cutoffs of alpha-fetoprotein screening for PIH could have the 
sensitivities and specificities of (12.5%, 92.6%), (25%, 88.9%), 
(75%, 71.6%) and (87.5%, 64.2%). 
Matemal serum alpha-fetoprotein screening at 22-23 week 
is a significant predictor for adverse outcomes because it can 
predict most outcomes including preterm delivety before 37 weeks, 
pregnancy induced hypertension and discordant growth. This 
would identify a group of twin pregnancies at increased risk for 
adverse outcomes or complications and thus allow more careful 
antenatal surveillance or invention to be administered earlier. 
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Twin pregnancies with discordant growth are problematic to 
obstetricians. They exhibit significantly poor physical and 
neurological development in both the childhood and the adult 
years (Babson et al” 1964 and 1973). The underlying pathology of 
this condition is an unbalanced flow of blood from one twin to 
another through vascular communications in the placenta. 
Eventually, the recipient twin grows to the detriment of the donor 
twin (D'Alton and Simpson, 1995). 
Treatment options include medical therapies such as 
indomethacin and digoxin, and more invasive intervention such as 
therapeutic amniocentesis and laser ablation of vascular 
communications. Therapeutic amniocentesis enables drainage of 
amniotic fluid to maintain a normal amniotic volume in each sac 
(Elliot et al, 1991). Intra-uterine laser ablation of vascular 
communications identified by fetoscopy is successful when twin-
twin transfusion syndrome is the cause of growth discordant (De 
Lia etal, 1990). 
As shown in Figure IV.11，the paired sensitivity and 
specificity of using MSAFP to predict growth discordant are (11.8% 
and 98.6%) or (17.6% and 95.8%) or (35.3% and 84.7%) or (52.9% 
and 62.5%). 
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V.C. Adjustment of Alpha-fetoprotein and Human 
Chorionic Gonadotrophin for Matemal Weight and 
Gestational Age 
Maternal serum alpha-fetoprotein and human chorionic 
gonadotrophin concentration vary considerably with gestational 
age (Figure W.1 and IV.2). Because most biological processes 
follow exponential changes, I believed that logarithm 
transformation could change the relationship between both 
hormones and gestational age to a linear one, which was 
confirmed in my data. ln(AFP) and ln(hCG) show linear relations 
with gestational age (for ln(AFP) and gestational age, r=0.7914, 
p=0.000; for ln(hCG) and gestational age, r=-0.5246, p=0.000). By 
linear regression of ln(AFP) and gestational age, and ln(hCG) and 
gestational age, we can adjust both hormones with gestational age. 
Besides, matemal weight is also a biological variable known 
to affect matemal serum alpha-fetoprotein and human chorionic 
gonadotrophin concentrations. Large women commonly have lower 
maternal serum concentrations of both hormones because alpha-
fetoprotein is produced by fetal liver and human chorionic 
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gonadotrophin is produced by syncytiotrophoblast，both are 
diluted in the greater intravascular blood volume of large women. 
In contrast, small women generally have high concentrations of 
both hormones because of their small volume of distribution. 
Thus, adjustment for the difference in matemal vascular blood 
volume should be used. 
It appears strange that maternal weight on univariate 
analysis is not significantly related to AFP but on multiple 
regression become a significant factor. This was probably due to 
the fact that matemal weight increases with advancing gestational 
age while these 2 parameters exert opposite effects on AFP 
concentration. Because gestational age has a stronger effect on 
AFP, it masked the effect of matemal weight on AFP by univariate 
analysis in which gestational age has not been controlled for. 
A formula corrected for gestational age and matemal weight 
can yield a value (AFPi or hCGi) which is independent of 
gestational age and matemal weight. AFPi is a ratio of the 
difference between expected and true values of ln(AFP) to the 
standard deviation of residual and is a value independent of 
gestational age and matemal weight whereas hCGi is a ratio of the 
difference between expected and true values of ln(hCG) to the 
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standard deviation of residual and is a value independent of 
gestational age and maternal weight. 
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V.D. Predictiveness of Alpha-fetoprotein and Human 
Chorionic Gonadotrophin for Adverse Outcomes after 
Matemal Weight and Gestation Age Adjustment 
AFPi is significantly related to preterm delivety at 18-24 
weeks. The area under curve of AFPi screening at 24 week is the 
greatest among the weeks of sampling with significant difference 
from the line of no accuracy. This implies that 24 week may be the 
optimal period for AFPi screening for preterm deliveity. AFPi is 
significantly related to spontaneous preterm deliveries at 18-19 
and 24 week whereas hCGi is significantly related to preterm 
deliveries only at 24 week and significantly related to spontaneous 
preterm deliveries at 16-19 and 22-23 weeks. The optimal period 
for hCGi screening may be 18-19. The turning points of AFPi as a 
test at 24 week to screen for preterm deliveries have the 
sensitivities and specificities of (22.2% and 93.9%) or (55.6% and 
81.8%) or (88.9% and 54.5%) whereas the turning points of AFPi 
as a test at 24 week to screen for spontaneous preterm deliveries 
have the sensitivities and specificities of (23.1% and 92.1%) or 
(61.5% and 78.9%) or (92.3% and 50%). 
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AFPi is not significantly related to premature delivety (<34 
week) whereas hCGi is significantly related to premature delivety 
at 14-17 week and 24 week. However, when we restrict the cases 
of premature deliveries to those with spontaneous onset only, AFPi 
is still not significantly related to premature delivety whereas hCGi 
is significantly related to premature delivery at 14-15 week, 18-19 
week and 24 week. The curve of hCGi as a test to screen 
premature deliveries at 24 week has the greatest area under curve 
and its tuming points have the sensitivities and specificities of 
(22.2% and 93.2%) or (44.4% and 81.8%) or (77.8% and 59.1%). 
AFPi is significantly related to most adverse outcomes at 22-
23 week. We should choose a screening test with the fewest 
analyst and predictive for most outcomes. AFPi assessment at 22-
23 week seems to be most suitable for this aim. 
V.E. Conclusions 
Chinese twin pregnancies as well as singleton pregnancies 
exhibit higher maternal serum alpha-fetoprotein and human 
chorionic gonadotrophin concentration during mid-trimester. 
Consequently, we should build our own data base of maternal 
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serum alpha-fetoprotein and human chorionic gonadotrophin 
concentration. In addition, twin pregnancies exhibit a significantly 
higher matemal serum alpha-fetoprotein and human chorionic 
gonadotrophin concentration than singleton pregnancies. The 
establishment of data base of serum concentration of both 
hormones in normal Chinese twin pregnancies provides reference 
values for Down's syndrome screening and open neural tube 
defects screening. 
In twin pregnancies, women with elevated matemal serum 
alpha-fetoprotein or human chorionic gonadotrophin 
concentration may not be explained by open neural tube defects or 
fetal Down's syndrome. It was well documented that a relation of 
elevated serum alpha-fetoprotein and human chorionic 
gonadotrophin with adverse outcomes (Hong et al” 1996; Johnson 
et al, 1990; Walker and Patel, 1986; Redford and Whitfield, 1985; 
Wald et al, 1978) and was confirmed in my study. In my study, 
alpha-fetoprotein seems to be superior to human chorionic 
gonadotrophin as a test to screen for adverse outcomes because 
alpha-fetoprotein or AFPi is significantly related to most adverse 
outcomes and for a wider period. Alpha-fetoprotein is significantly 
related to most adverse outcomes at 22-23 week. After matemal 
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weight and gestational age adjustment, AFPi is significantly related 
to most adverse outcomes. 
AFPi or hCGi does not appear to yield a better result 
compared with conventional method of analysis by multiples of the 
median (MoM) without matemal weight adjustment. This may be 
accounted by the fact that gestational age is the major biological 
dependent variable and the effect of matemal weight is much 
small. 
Although I have shown that alpha-fetoprotein and human 
chorionic gonadotrophin are significantly related to poor obstetric 
outcomes, the clinical value of using these 2 hormones as 
screening test for adverse pregnancy outcomes is probably limited 
because of the undesirable sensitivities and specificities of the test 
as shown in section V.B and V.D. However, if AFP is tested for 
other indication and is subsequently found to be abnormal (> 2 
MoM，most of these pregnancies will have some form of adverse 
outcome and therefore require close surveillance. For instance, 
ultrasound assessment of the fetuses may not be performed before 
a screening test for Down's syndrome is performed and the 
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physician may not realize that the patient has a twin pregnancy. 
When the patient is found to have a matemal serum alpha-
fetoprotein concentration greater than 2 multiples of the medians 
for twin pregnancies, they are likely to have adverse pregnancy 
outcome or complication. Special antenatal surveillance should be 
offered to these patients. 
V.F. Future Directions 
The performance of maternal serum alpha-fetoprotein and 
human chorionic gonadotrophin as a screening test for adverse 
pregnancy outcomes is not very satisfactoty at present form. 
Future study should aim to look for other markers for adverse 
pregnancy outcomes or the combined use of these hormones. 
Potential markers might be other placental proteins such as 




DATA BASE OF CLINICAL INFORMATION 
Date of Birth 
Gravida 
Parity 
Expected Date of Delivety 
Date of Delivery 
Days of Admission Before Delivety 
Pregnancy Induced Hypertension 






Onset of Labour spontaneous 
induced 
elective low section caesarean 
section 
Induction of Labour none/ irrelevant 
prostaglandin 
oxytocin 
artificial rupture of 
membrane 
(ARM) 
prostaglandin + oxytocin 
prostaglandin + ARM 
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oxytocin + ARM 
prostaglandin + oxytocin + 
ARM 
Indication of Induction of Labour none/irrelevant 
diabetes/gestational diabetes 
maternal disease 
bad obstetric histoty 
past term 
hypertension 











diabetes + hypertension 
Augmentation 
Mode of Augmentation none/irrelevant 
ARM 
ARM + o;jQ t^ocin 
oxytocin 












Indication for Instrumental Delivery (Twin 1) none/irrelevant 
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maternal disease 




prolonged second stage 
others 
Indication for Instrumental Delivery (Twin 2) none/irrelevant 
matemal disease 




prolonged second stage 
others 
Indication for Caesarean Section (Twin 1) none/irrelevant 
diabetes/gestational diabetes 
matemal disease 
previous uterine scar 












failed instrument^ delivety 
tumour/anomajiy 
failed induction 




Indication for Caesarean Section (Twin 2) none/irrelevant 
diabetes/gestational diabetes 
matemal disease 
previous uterine scar 
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malpresentation / lie 
no progress 
cephalopelvic disproportion 
cp/ unfavourable pel 
failed instrumental delivety 
tumour/anomaly 
failed induction 












Sex (Twin 1) 
Sex (Twin 2) 
Birth Weight (Twin 1) 
Birth Weight (Twin 2) 
Apgar Score at 1 minute (Twin 1) 
Apgar Score at 1 minute (Twin 2) 
Apgar Score at 5 minutes (Twin 1) 
Apgar Score at 5 minutes (Twin 2) 
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I 
Placental Weight (Twin 1) 
Placental Weight (Twin 2) 
Cord pH (Twin 1) artety 
vein 




SEVERITY AND CLASSIFICATION OF 
PREGNANCY INDUCED HYPERTENSION 
Severity 
Hypertension/Eclampsia no 
mild diastolic blood pressure < 110 mmHg 
and no proteinuria 





gestational blood pressure normal before 20 weeks 
hypertension and no previous history of 
hypertension; 
diastoUc blood pressure > 110 mmHg 
on any occassion or > 90 mmHg on 2 
occasions at least 4 hours apart 
gestational proteinuria > 300 mg/ 24 hours or 2 
proteinuria MSU/CSU collected > 4 hours apart 
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